Clinical Research Directory
Browse clinical research sites, groups, and studies.
Roxadustat Versus Erythropoietin for Anaemia Treatment in Diabetic Nephropathy
Sponsor: Hanzla Arshad
Summary
This randomized controlled trial compared roxadustat with erythropoietin for the treatment of anaemia in patients with diabetic nephropathy and chronic kidney disease. A total of 64 patients aged 18 to 75 years were enrolled at the Department of Nephrology, Sheikh Zayed Hospital, Lahore, and randomly assigned in a 1:1 ratio to two treatment groups. Participants in the roxadustat group received roxadustat 100 mg orally three times per week, while participants in the erythropoietin group received recombinant erythropoietin 4000 IU subcutaneously twice weekly. Participants were followed for three months. The primary objective was to compare the change in haemoglobin level between the two treatment groups after treatment.
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
64
Start Date
2025-12-20
Completion Date
2026-06-20
Last Updated
2026-08-25
Healthy Volunteers
No
Interventions
Roxadustat
Roxadustat 100 mg was administered orally three times per week for three months.
Erythropoietin
Recombinant erythropoietin 4000 IU was administered by subcutaneous injection twice weekly for three months.
Locations (1)
Sheikh Zayed Hospital
Lahore, Pakistan